07-Feb-2023 | Facts and Factors
According to Facts and Factors, the global kinase inhibitor in autoimmune diseases market size was worth around USD 4.7 billion in 2021 and is predicted to grow to around USD 7.9 billion by 2030 with a compound annual growth rate (CAGR) of roughly 5.43% between 2022 and 2030.
Kinase inhibitor is a substance that is used to block kinase, a type of enzyme. The human body comprises different types of kinases since they help in controlling critical functions like metabolism, signaling, survival, and division. There are certain kinases that are more active than others and blocking these kinases can help in preventing different types of medical conditions like autoimmune diseases or cancer. Various types of kinase inhibitors are already present in the market or in the development phase specifically targeting autoimmune diseases.
Browse the full “Kinase Inhibitor In Autoimmune Diseases Market Size, Share, Growth Analysis Report By Drug (Corticosteroids, Anti-Inflammatory Drugs, Immunosuppressants, and Pain-Killing Medications), By Treatment (Deficiency Treatment, Physical Therapy, and Surgery), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2030" report at https://www.fnfresearch.com/kinase-inhibitor-in-autoimmune-diseases-market
For instance, currently, the medical research community is heavily focusing on Bruton’s tyrosine kinase (BTK), an important signaling protein that is directly linked to B-cell receptor (BCR) signals for activating B-cell, followed by proliferation and survival. Since BTK is also expressed in myeloid cells and involves various signaling techniques that directly contribute to the autoimmune system, BTK has become a well-studied therapeutic agent for the treatment of autoimmune conditions.
The global kinase inhibitor in autoimmune diseases market is projected to grow due to growing investments in the healthcare community as well as increasing information related to the causes and treatments of various autoimmune diseases, which can be triggered by various environmental and genetic factors. The global market may additionally benefit from the increasing number of drugs in the pipeline awaiting approval from different regional regulatory bodies.
In November 2022, the European Commission (EC) approved the use of Enjaymo® (sutimlimab) for treating hemolytic anemia observed in adult patients who are suffering from cold agglutinin disease (CAD) which is a serious case of chronic autoimmune hemolytic anemia that is rare but has affected a significant number of people. In this condition, the body’s immune system starts attacking the healthy blood cells and causes them to rupture also called hemolysis. Growing government efforts to increase access to quality medical care like the Patient Protection Act or Affordable Care Act could further fuel the global market growth.
However, there are several complexities that are associated with designing the right and effective kinase inhibitor along with achieving accurate target selectivity which could potentially impact the global market growth. Minimizing the effects in case of off-sets could also damage the otherwise smooth growth trend of the global market. In theory, various kinases can be identified but the interpretation of data becomes difficult in case large numbers of kinases are getting inhibited.
The growing strategic measures adopted by market players could create growth opportunities while the high cost of development may challenge market growth.
Segmental Overview:
The global kinase inhibitor in autoimmune diseases market is segmented based on drug, treatment, and region
Based on drug, the global market segments are corticosteroids, anti-inflammatory drugs, immunosuppressants, and pain-killing medications. The global market is anticipated to be led by the anti-inflammatory drugs segment in the coming years as it did in 2021. More than 43% of the global market share was led by the growing applications and use of anti-inflammatory drugs. The medicines are available at lower costs and show high-performance value. Anti-inflammatory drugs are more beneficial than steroids because they do not showcase any significant side effects making them highly sought-after drugs in the medical community.
Based on treatment, the global market is divided into deficiency treatment, physical therapy, and surgery. The global market registered the highest growth in the applications of drugs for deficiency treatment which is one of the main reasons for many autoimmune diseases. Most doctors recommend undergoing regular blood checkups as it can potentially help in reversing autoimmune diseases and preventing the occurrence of any other condition. For instance, vitamin D deficiency is known to cause rheumatoid arthritis which affects more than 1.29 million people in the US.
Regional Overview:
North America is anticipated to lead the global kinase inhibitor in the autoimmune diseases market due to the growing number of patients suffering from the condition as well as the high awareness rate allowing them to undertake the right medication plan. As per estimated around 1 in every 100,000 people in the US is affected by Addison's disease. The condition is caused when the body stops making the required amount of hormones.
The regional growth may also register a high CAGR due to the high accessibility to quality medical care encouraged by the availability of medical reimbursements. More than 76% of Canadian citizens had access to life and health insurance. Growth in Asia-Pacific is projected to be led by the growing revenue in the healthcare and pharmaceutical segment as well as the rising entry of international players in countries like Japan, India, and China.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 4.7 Billion |
Projected Market Size in 2030 |
USD 7.9 Billion |
CAGR Growth Rate |
5.43% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2030 |
Key Market Players |
Boehringer Ingelheim International GmbH, Akorn Incorporated, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Mylan N.V., and Others |
Key Segment |
By Treatment, Food Source, End-Users, Diagnosis, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Competitive Landscape:
The global kinase inhibitor in autoimmune diseases market is dominated by players like Gilead Sciences, Reistone Biopharma, Japan Tobacco and Torii Pharmaceutical, Eli Lily and Company, Astellas Pharma, Pfizer, and Galapagos NV.
Recent Developments:
- In August 2021, Reistone Biopharma announced that the phase 2 study of SHR0302 had shown promising results. Reistone Biopharma focuses on the development of treatment methodologies for inflammation and immune disorders. The study evaluated the safety concerns related to SHR0302 which is a drug used to treat severe alopecia in adults
- In December 2022, HotSpot Therapeutics, Inc. and AbbVie declared a collaboration intended toward the licensing of the IRF5 program developed by HotSpot which is in its discovery stage. The program will aid the treatment of autoimmune diseases
The global kinase inhibitor in autoimmune diseases market is segmented as follows:
By Drug
- Corticosteroids
- Anti-Inflammatory Drugs
- Immunosuppressants
- Pain-Killing Medications
By Treatment
- Deficiency Treatment
- Physical Therapy
- Surgery
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
